Tyra Biosciences/TYRA

$16.03

3.42%
-
1D1W1MYTD1YMAX

About Tyra Biosciences

Tyra Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. Its initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. Its lead product candidate, TYRA-300, is an investigational, oral, FGFR3-selective inhibitor being evaluated in an international, multi-center, open label Phase 1 clinical study, SURF301. Its second oncology product candidate, TYRA-200, is an investigational, oral, FGFR1/2/3 inhibitor with potency against activating FGFR2 gene alterations, and clinically important molecular brake and gatekeeper resistance mutations.

Ticker

TYRA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Todd Harris

Employees

49

Headquarters

Carlsbad, United States
Website
tyra.bio

Tyra Biosciences Metrics

BasicAdvanced
$786.77M
Market cap
-
P/E ratio
-$1.62
EPS
-
Beta
-
Dividend rate
$786.77M
$20.67
$10.38
139.85K
13.805
-28.1%
-29.92%
-29.36%
3.155
3.852
-22.33%

What the Analysts think about Tyra Biosciences

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 5 analysts.
53.46% upside
High $28.00
Low $22.00
$16.03
Current price
$24.60
Average price target

Tyra Biosciences Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-22.8M
8.06%
Profit margin
0%
-

Tyra Biosciences Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 10.26%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.28
-$0.31
-$0.49
-$0.53
-
Expected
-$0.37
-$0.34
-$0.35
-$0.48
-$0.46
Surprise
-23.5%
-9.8%
38.94%
10.26%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Tyra Biosciences stock?

Tyra Biosciences (TYRA) has a market cap of $786.77M as of April 23, 2024.

What is the P/E ratio for Tyra Biosciences stock?

The price to earnings (P/E) ratio for Tyra Biosciences (TYRA) stock is 0 as of April 23, 2024.

Does Tyra Biosciences stock pay dividends?

No, Tyra Biosciences (TYRA) stock does not pay dividends to its shareholders as of April 23, 2024.

When is the next Tyra Biosciences dividend payment date?

Tyra Biosciences (TYRA) stock does not pay dividends to its shareholders.

What is the beta indicator for Tyra Biosciences?

Tyra Biosciences (TYRA) does not currently have a Beta indicator.

What is the Tyra Biosciences stock price target?

The target price for Tyra Biosciences (TYRA) stock is $24.6, which is 52.23% above the current price of $16.16. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Tyra Biosciences stock

Buy or sell Tyra Biosciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing